Regeneron shares fall after FDA rejects high-dose eye disease treatment - Stock Check Updates

Breaking

Tuesday, June 27, 2023

Regeneron shares fall after FDA rejects high-dose eye disease treatment

Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler."

from International: Top News And Analysis https://ift.tt/AnXYdCJ
via IFTTT

No comments:

Post a Comment